Business Context and Reporting Period
This Form 8-K filing by Ironwood Pharmaceuticals, Inc. (IRWD) reports a material event dated November 25, 2025. The company is a Delaware corporation with its principal executive offices in Boston, Massachusetts. The filing addresses regulatory developments under the Inflation Reduction Act of 2022.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. It is a current report focused on a specific regulatory event rather than periodic financial performance.
Material Changes and Events
Under Item 8.01 (Other Events), the U.S. Department of Health and Human Services (HHS) announced the "Maximum Fair Price" (MFP) for the company's product LINZESS (linaclotide). Key details include:
- Product: LINZESS (linaclotide).
- MFP Amount: $136 for a 30-day equivalent supply.
- Effective Date: The new Medicare net price will take effect on January 1, 2027.
- Context: This price setting is part of the most recent round of government price negotiations under the Inflation Reduction Act of 2022.
Management Commentary and Outlook
Management stated that the revised MFP for LINZESS is "in line with the expectations of Ironwood Pharmaceuticals, Inc." The filing does not provide additional forward-looking guidance, risk factors, or contingencies beyond this specific pricing announcement.
Investor Verification Checklist
- Verify the impact of the $136 MFP on projected 2027 and subsequent revenue streams for LINZESS.
- Confirm the exact effective date of January 1, 2027, for the new Medicare net price.
- Review the company's previous guidance to assess if the "in line with expectations" statement implies no material deviation from prior models.
- Monitor future filings for any updates regarding other products potentially subject to the Inflation Reduction Act.